Contraindications for Evenity (Romosozumab)
Evenity (romosozumab) is contraindicated in patients with hypocalcemia, history of myocardial infarction or stroke within the preceding year, and history of systemic hypersensitivity to romosozumab or any component of the formulation. 1
Absolute Contraindications
Hypocalcemia
Hypersensitivity
Recent Cardiovascular Events
Relative Contraindications/Use with Caution
High Cardiovascular Risk
Pregnancy and Breastfeeding
Open Growth Plates
Patient Populations Where Alternative Therapies Are Preferred
Low Fracture Risk Patients
Moderate Fracture Risk Patients
Solid Organ Transplant Recipients
Monitoring Requirements
If romosozumab is prescribed despite relative contraindications:
Calcium Levels
Cardiovascular Monitoring
Treatment Duration Limitations
- Romosozumab treatment is limited to 12 monthly doses 1
- After completion, patients should transition to an antiresorptive agent to maintain bone mineral density gains 3, 8
Practical Considerations
- Romosozumab should be reserved for postmenopausal women at highest risk for fracture with low cardiovascular risk 4, 8
- The ideal use in the therapeutic sequence is as first-line treatment in case of a recent major fracture in patients without cardiovascular contraindications 2
- For patients with high or very high fracture risk but cardiovascular concerns, alternative treatments such as PTH/PTHrP analogs or denosumab may be preferred 5, 6
Remember that the risk-benefit assessment is particularly important with romosozumab, as it has demonstrated significant fracture reduction efficacy but carries cardiovascular safety concerns that require careful patient selection.